Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 437

The DOI matches its Crossref record; 337 of the 337 references it cites were found in a registry or an index.

Applications of single-cell RNA sequencing in drug discovery and development

Open access
Van de Sande, Bram, Lee, Joon Sang, Mutasa-Gottgens, Euphemia, Naughton, Bart, Bacon, Wendi, Manning, Jonathan, Wang, Yong, Pollard, Jack, Mendez, Melissa, Hill, Jon, Kumar, Namit, Cao, Xiaohong, Chen, Xiao, Khaladkar, Mugdha, Wen, Ji, Leach, Andrew, Ferran, Edgardo·2023·Nature Reviews Drug Discovery

Abstract

Single-cell technologies, particularly single-cell RNA sequencing (scRNA-seq) methods, together with associated computational tools and the growing availability of public data resources, are transforming drug discovery and development. New opportunities are emerging in target identification owing to improved disease understanding through cell subtyping, and highly multiplexed functional genomics screens incorporating scRNA-seq are enhancing target credentialling and prioritization. ScRNA-seq is also aiding the selection of relevant preclinical disease models and providing new insights into drug mechanisms of action. In clinical development, scRNA-seq can inform decision-making via improved biomarker identification for patient stratification and more precise monitoring of drug response and disease progression. Here, we illustrate how scRNA-seq methods are being applied in key steps in drug discovery and development, and discuss ongoing challenges for their implementation in the pharmaceutical industry. There have been significant recent advances in the development of single-cell technologies, providing remarkable opportunities for drug discovery and development. Here, Ferran and colleagues discuss how single-cell technologies, primarily single-cell RNA sequencing methods, are being applied in the drug discovery pipeline, from target identification to clinical decision-making. Ongoing challenges and potential future directions are discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41573-023-00688-4

Cites

337 of 337 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 337 references

Cited by

See all 437

Metadata

Authors
Van de Sande, B., Lee, J. S., Mutasa-Gottgens, E., Naughton, B., Bacon, W., Manning, J., Wang, Y., Pollard, J., Mendez, M., Hill, J., Kumar, N., Cao, X., Chen, X., Khaladkar, M., Wen, J., Leach, A., & Ferran, E.
Venue
Nature Reviews Drug Discovery
Published
2023-04-28
Volume
22
Issue
6
Pages
496-520
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W4367312557
Cited by
437
References
337
FWCI
11.12
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Applications of single-cell RNA sequencing in drug discovery and development. https://app.cochat.ai/papers/10.1038/s41573-023-00688-4
The paper
Van de Sande, B., Lee, J. S., Mutasa-Gottgens, E., Naughton, B., Bacon, W., Manning, J., Wang, Y., Pollard, J., Mendez, M., Hill, J., Kumar, N., Cao, X., Chen, X., Khaladkar, M., Wen, J., Leach, A., & Ferran, E. (2023). Applications of single-cell RNA sequencing in drug discovery and development. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-023-00688-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.